During mammary cell growth, prolactin suppresses BCL6 expression through a STAT5A-related mechanism, suggesting that loss of prolactin-STAT5A signaling and concomitant increases of BCL6 may constitute a regulatory switch and facilitate undifferentiated histology and poor prognosis of breast cancer [57]. This evidence concerns the gene BCL6 and breast carcinoma.